ARROWHEAD PHARMACEUTICALS, INC.

ARWR 10-K · FY 2025
API behind this page

ARWR FY 2025 request

Playground key active
Request URL /api/financials?ticker=ARWR&year=2025&quarter=4&full_year_mode=true
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric FY 2025 FY 2024 YoY
Revenue 829,448 3,551 +23258.2%
Show Counterparty Name breakouts
Sanofi · Sanofi License Agreement 130 — —
Sarepta 696.8 — —
Show Major Customers breakouts
GSK 2,645 2,685 -1.5%
Sanofi 130,000 — —
Sarepta 696,803 — —
Research & Development 607,159 505,870 +20.0%
Show Business Segments breakouts
Operating Segment 607,159 505,870 +20.0%
General & Administrative 123,943 98,761 +25.5%
Show Business Segments breakouts
Operating Segment 123,943 98,761 +25.5%
Operating Expenses 731,102 604,631 +20.9%
Operating Income 98,346 -601,080 +116.4%
Investment Income Interest And Dividend 37,289 22,720 +64.1%
Interest Expense -89,361 -32,352 -176.2%
Other Non-Operating Income (Expense) 5,259 -1,748 +400.9%
Non-Operating Income (Expense) -46,813 -11,380 -311.4%
Income Before Taxes 51,533 -612,460 +108.4%
Income Tax Expense (Benefit) 21,419 -2,767 +874.1%
Net Income 30,114 -609,693 +104.9%
Show Equity Components breakouts
Noncontrolling Interest 31,745 -10,200 +411.2%
Retained Earnings -1,631 -599,493 +99.7%
Net Income Loss Attributable To Noncontrolling Interest 31,745 -10,200 +411.2%
Net Income -1,631 -599,493 +99.7%
EPS (Basic) -0.01 -5 +99.8%
EPS (Diluted) -0.01 -5 +99.8%
Wtd Avg Shares (Basic) 133,758 119,784 +11.7%
Wtd Avg Shares (Diluted) 133,758 119,784 +11.7%
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax 2,125 3,775 -43.7%
Show Equity Components breakouts
Accumulated Other Comprehensive Income 2,125 3,775 -43.7%
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax -432 4,197 -110.3%
Show Equity Components breakouts
Accumulated Other Comprehensive Income -432 4,197 -110.3%
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest 31,745 -10,200 +411.2%
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest 31,807 -601,721 +105.3%
Professional Fees (FY) — — —
Show Business Segments breakouts
Operating Segment 53,589 24,733 +116.7%

Balance Sheet

Balance Sheet
Metric FY 2025 FY 2024 YoY
Current Assets
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 226,548 102,685 +120.6%
Show Consolidated Entities breakouts
Consolidated Entity Excluding Variable Interest Entities VIE 88,706 76,208 +16.4%
Variable Interest Entity Primary Beneficiary 137,842 26,477 +420.6%
Accounts Receivable 6,824 — —
Show Counterparty Name breakouts
Sarepta 6.8 — —
Available For Sale Securities Debt Securities Current 692,818 578,276 +19.8%
Show Financial Instrument breakouts
Debt Securities 692,818 578,276 +19.8%
Prepaid Expense Current 10,933 9,537 +14.6%
Other Assets Current 13,516 4,973 +171.8%
Total Current Assets 950,639 695,471 +36.7%
Non-Current Assets
Property, Plant & Equipment 382,515 386,032 -0.9%
Intangible Assets 6,861 8,562 -19.9%
Show Asset Acquisition breakouts
Novartis 6,861 8,562 -19.9%
Novartis · Licensing Agreements 1,559 1,707 -8.7%
Novartis · Patents 5,302 6,855 -22.7%
Operating Lease Right-of-Use Assets 43,891 45,255 -3.0%
Other Non-Current Assets 1,389 4,482 -69.0%
Total Assets 1,385,295 1,139,802 +21.5%
Current Liabilities
Accounts Payable 17,674 11,388 +55.2%
Accrued Liabilities 90,419 63,017 +43.5%
Show Counterparty Name breakouts
Takeda · License and Co-Funding Agreement 31.3 — —
Employee Related Liabilities Current 26,895 21,989 +22.3%
Operating Lease Liability Current 7,289 6,342 +14.9%
Deferred Revenue (Current) 2,399 — —
Lines Of Credit Current 40,000 — —
Show Debt Instrument breakouts
Financing Agreement · Secured Debt 40,000 — —
Show Credit Facility breakouts
Revolving Credit Facility · Line Of Credit 72.9 — —
Other Liabilities Current 10,811 432 +2402.5%
Total Current Liabilities 195,487 103,168 +89.5%
Non-Current Liabilities
Operating Lease Liabilities 104,112 111,027 -6.2%
Royalties Liability Noncurrent 367,397 341,361 +7.6%
Long Term Line Of Credit 214,883 393,183 -45.3%
Liabilities Noncurrent 686,392 845,571 -18.8%
Long-Term Debt (Q) — — —
Show Debt Instrument breakouts
Financing Agreement · Secured Debt 214,883 393,183 -45.3%
Stockholders' Equity
Common Stock 231 217 +6.5%
Additional Paid In Capital Common Stock 2,139,725 1,806,000 +18.5%
Accumulated Other Comprehensive Income 6,443 4,750 +35.6%
Retained Earnings -1,627,154 -1,625,523 -0.1%
Treasury Stock Common Value -53,193 — —
Total Stockholders' Equity 466,052 185,444 +151.3%
Minority Interest 37,364 5,619 +565.0%
Stockholders Equity Including Portion Attributable To Noncontrolling Interest 503,416 191,063 +163.5%
Show Equity Components breakouts
Accumulated Other Comprehensive Income 6,443 4,750 +35.6%
Additional Paid In Capital 2,139,725 1,806,000 +18.5%
Common Stock 231 217 +6.5%
Noncontrolling Interest 37,364 5,619 +565.0%
Retained Earnings -1,627,154 -1,625,523 -0.1%
Treasury Stock Common -53,193 — —
Total Liabilities & Equity 1,385,295 1,139,802 +21.5%

Cash Flow Statement

Cash Flow Statement
Metric FY 2025 FY 2024 YoY
Operating Activities
Stock-Based Compensation 63,366 73,968 -14.3%
Depreciation And Amortization 23,928 18,595 +28.7%
Investment Income Net Amortization Of Discount And Premium -5,789 -3,244 -78.5%
Noncash Interest Expense Liability Related To Sale Of Future Royalties 26,036 23,035 +13.0%
Paid In Kind Interest 63,325 9,317 +579.7%
Gain Loss On Treasury Stock Settlement -3,193 — —
Change in Accounts Receivable -56,967 — —
Change in Prepaid & Other Assets -9,939 -1,664 -497.3%
Change in Accounts Payable 6,286 -5,536 +213.5%
Increase Decrease In Accrued Liabilities 41,497 32,117 +29.2%
Change in Deferred Revenue 2,399 -866 +377.0%
Increase Decrease In Operating Lease Liability -4,605 2,240 -305.6%
Increase Decrease In Other Operating Capital Net 3,094 -1,200 +357.8%
Net Cash from Operations 179,552 -462,851 +138.8%
Depreciation & Amortization 22.2 16.9 +31.4%
Show Business Segments breakouts
Operating Segment · General And Administrative Expense 2,028 1,941 +4.5%
Operating Segment · Research And Development Expense 21,900 16,654 +31.5%
Investing Activities
Capital Expenditures -22,666 -141,469 +84.0%
Payments To Acquire Investments -796,258 -720,947 -10.4%
Proceeds From Sale Maturity And Collections Of Investments 689,630 442,344 +55.9%
Net Cash from Investing -129,294 -420,072 +69.2%
Financing Activities
Proceeds From Stock Options Exercised 3,983 2,389 +66.7%
Proceeds From Issuance Of Common Stock 241,388 429,265 -43.8%
Proceeds From Issuance Of Warrants 25,000 — —
Debt Issuance Costs -5,000 -3,134 -59.5%
Repayments Of Long Term Lines Of Credit -201,625 — —
Show Debt Instrument breakouts
Financing Agreement · Secured Debt -201.6 — —
Proceeds From Lines Of Credit 10,260 — —
Net Cash from Financing 74,006 870,520 -91.5%
Supplemental
Interest Paid -19 — —
Income Taxes Paid 814 -3,744 +121.7%
Treasury Stock Received In Exchange For Settlement Of Accounts Receivable 50,000 — —
Unpaid Capital Expenditures 277 4,206 -93.4%
Other Cash Flow
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect 124,264 -12,403 +1101.9%
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents -401 4,197 -109.6%

Values in thousands USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key